M.E. AKSENOVA

Veltischev Research and Clinical Institute for Pediatrics of the Pirogov Russian National Research Medical University, 2 Taldomskaya Str., Moscow, Russian Federation, 125412

Aksenova M.E. – PhD (medicine), Leading Research Associate of the Department of Hereditary and Acquired Kidney Diseases, tel. (495) 483-21-83, e-mail: maksyonova@pedklin.ru

Cardiovascular pathology is known to be the main complication of chronic kidney diseases. Based on literature and own data, it was testified that the incidence of cardiovascular pathology in adults and children with chronic kidney diseases, the prevalence of traditional and nephrogenic cardiovascular risk factors increases depending on the stage of chronic kidney disease. The article describes the main mechanisms for the development of endothelial dysfunction, vascular atherosclerosis, calcification of the vascular wall, and myocardial remodeling in patients with chronic kidney disease, including possible mechanisms of influence of prednisolone and calcineurin blockers. By the example of patients with nephrotic syndrome, including genetically determined, Alport syndrome and autosomal dominant polycystic disease, it was demonstrated that the features of cardiovascular pathology can be determined by the nature of the nephrological disease.

Key words: chronic kidney disease, cardiovascular pathology, risk factors, arterial hypertension, left ventricular remodeling, endothelial dysfunction, dyslipidemia, phosphorus-calcium metabolism, oxidative stress.

(For citation: M.E. Aksenova Development mechanisms of cardiovascular pathology in chronic kidney diseases. Practical Medicine. 2018)

REFERENCES

1. Collins A.J., Li S., Gilbertson D.T., Liu J. et al. Chronic kidney disease and cardiovascular disease in the Medicare population. Kidney Intern, 2003, vol. 64; suppl. 87, pp. 24-31.
2. Bansal N., Katz M.R., Robinson-Cohen C. Absolute Rates of Heart Failure, Coronary Heart Disease, and Stroke in Chronic Kidney Disease. An Analysis of 3 Community-Based Cohort Studies. JAMA Cardiol., 2017, vol. 2, no. 3, pp. 314-318.
3. Dennis V.W. Coronary Heart Disease in Patients with Chronic Kidney Disease. J Am Soc Nephrol., 2005, vol. 16, pp. 103-106.
4. Cai Q., Mukku V.K., Ahmad M. Coronary Artery Disease in Patients with Chronic Kidney Disease: A Clinical Update. Current Cardiology Reviews, 2013, no. 9, pp. 331-339.
5. Shiba N., Shimokawa H. Chronic kidney disease and heart failure — Bidirectional close link and common therapeutic goal. J of Cardiology, 2011, vol. 57, pp. 8-17.
6. Chen X-N., Pan X-X., Yu H-J., Shen P-Y., Zhang Q-Y., al. Analysis of Cardiovascular Disease in Chinese Inpatients with Chronic Kidney Disease. Intern Med, 2011, vol. 50, pp. 1797-1801.
7. Yahalom G., Kivity S., Segev S., Sidi Y. et al. Estimated glomerular filtration rate in population with normal to mildly reduce renal function as predictor of cardiovascular disease. Eur J Prev Cardiol., 2014.
8. Chen S., Chang J., Liu W., Huang J.C. et al. Echocardiographic parameters are independently associated with increased cardiovascular events in patients with chronic kidney disease. Nephrol Dial Transplant., 2012, vol. 27, pp.1064-1070.

9. Mitsnefes M. Cardiovascular complications of pediatric chronic kidney disease. Pediatr Nephrol, 2008, no. 1, pp. 27–39.
10. Furth S., Abraham A., Jerry-Fluker J., Schwartz G.J. et al. Metabolic abnormalities, cardiovascular disease risk factors, and GFR decline in children with chronic kidney disease. Clin J Am Soc Nephrol, 2011, no. 9, pp. 2132-2140.
11. Wilson A., Schneider M., Cox C., Greenbaum L.A. et al. Prevalence and correlates of multiple cardiovascular risk factors in children with chronic kidney disease. Clin J Am Soc Nephrol, 2011, vol. 6, no. 12, pp. 2759-2765.
12. Rostand S., Drüeke T. Parathyroid hormone, vitamin D and cardiovascular disease in chronic renal failure. Kidney Int, 1999, vol. 56, pp. 383-392.
13. Fadrowski J. Hemoglobin decline in children with chronic kidney disease: baseline results from the Chronic Kidney Disease in Children Prospective Cohort Study. Clin J Am Soc Nephrol., 2008, no. 3, pp. 457-462.
14. Wang C-P., Lu L-F., Yu T-H., Hung W.C., al. Association among chronic kidney disease, high total p-cresylsulfate and major adverse cardiac events. J Nephrol., 2013, vol. 26, pp. 111-118.
15. Garcia-Bello JA, Gómez-Díaz R.A., Contreras-Rodríguez A. Carotid intima media thickness, oxidative stress, and inflammation in children with chronic kidney disease. Pediatr Nephrol., 2014, vol. 29, pp. 273-281.
16. Tang W., Lu Y., Tian Q.Y. The growth factor progranulin bends TNF receptors and is therapeutic against inflammatory arthritis in mice. Science, 2011, vol. 332, pp. 478-484.
17. Fu Y., Sun Y., Zhou M., Wang X., Wang Z. et al. Therapeutic potential of progranulin in hyperhomocysteinemia-induced cardiorenal dysfunction. Hypertension, 2017, vol. 69, no. 2, pp. 259-266.
18. Matsuguma K., Ueda S., Yamagishi S. Molecular mechanism for elevation of asymmetric dimethylarginine and its role for hypertension in chronic kidney disease. J Am Soc Nephrol., 2006, vol. 17, pp. 2176-2183.
19. Jonson R.C., Leopold J.A., Loscalzo J. Vascular calcification: pathobiological mechanisms and clinical implication. Circ Res, 2006, vol. 99, pp. 1044-1059.
20. Takeda S., Elefteriou F., Levasseur R. et al. Leptin regulates bone formation via the sympathetic nervous system. Cell, 2002, vol. 111, pp. 305-317.
21. Kupferman J., Friedman A., Cox C. et al. CKiD Study Group. BP control and left ventricular hypertrophy regression in children with CKD. J Am Soc Nephrol, 2014, vol. 25, pp. 167-174.
22. Kennedy D.J., Malhotra D., Shapiro J.I. Molecular insights into uremic cardiomyopathy: cardiotonic steroids and Na/K ATPase signaling. Cell Mol Biol, 2006, vol. 52, pp. 3-14.
23. Despa S., Lingrel J.B. Na+/K+-ATPase α2-isoform preferentially modulates Ca2+ transients and sarcoplasmic reticulum Ca2+ release in cardiac myocytes. Cardiovasc Res., 2012, vol. 95, pp. 480–486.
24. Semple D., Smith K., Bhandari S. et al. Uremic cardiomyopathy and insulin resistance: a critical role for akt? J Am Soc Nephrol, 2011, vol. 22, pp. 207-215.
25. Briet M., Schiffrin E.L. Aldosterone: effects on the kidney and cardiovascular system. Nature Reviews Nephrology, 2010, no. 6, pp. 261-273.
26. Andersson P., Rydberg E., Willenheimer R. Primary hyperparathyroidism and heart disease. Eur Heart J, 2004, vol.25, pp. 1776-1787.

27. Agarwal I., Ide N., Ix J.H. et al. Fibroblast growth factor-23 and cardiac structure and function. J Am Heart Assoc., 2014, vol. 13, e000584.
28. Juppner H., Wolf M., Salusky I.B. FGF23: more than a regulator of renal phosphate handling? J Bone Miner Res, 2010, vol. 25, pp. 2091-2097.
29. Liu Y-L., Huang C-C., Chang C-C., Chou C-Y., al. Hyperphosphate-Induced Myocardial Hypertrophy through the GATA-4/NFAT-3 Signaling Pathway Is Attenuated by ERK Inhibitor Treatment. Cardiorenal Med, 2015, no. 5, pp. 79–88.
30. Lindblad Y.T., Olauson H., Vavilis G., Hammar U. et al. The FGF23-Klotho axis and cardiac tissue Doppler imaging in pediatric chronic kidney disease – a prospective cohort study. Pediatr Nephrol, 2018, vol. 33, pp. 147-157.
31. Panizo S., Barrio-Vazquez S., Naves-Diaz M. Vitamin D receptor activation, left ventricular hypertrophy and myocardial fibrosis. Nephrol Dial Transplant, 2013, vol. 28, pp. 2735-2744.
32. Shroff R. A bimodal association of vitamin D levels and vascular disease in children on dialysis. J Am Soc Nephrol, 2008, vol. 19, pp. 1239-1269.
33. Zittermann A., Schleitgoff S.S., Koerfer R. Putting cardiovascular disease and vitamin D insufficiency into perspective. Br J Nutr, 2005, vol. 94, pp. 483-492.
34. Badve S.V., Palmer S.C., Strippoli G.F. The validity of left ventricular mass as a surrogate end point for all-cause and cardiovascular mortality outcomes in people with CKD: a systematic review and meta-analysis. Am J Kidney Disease, 2016, vol. 68, pp. 554-563.
35. Rutherford E., Talle M.A., Mangion K. Defining myocardial tissue abnormalities in end-stage renal failure with cardiac magnetic resonance imaging using native T1 mapping. Kidney Int, 2016, vol. 90, pp. 845-852.
36. Dwivedi J., Sarkar P. Oxidative stress in secondary nephrotic syndrome: recent advance with homocysteine, copper and zinc. Biomed & Pharmacol J, 2009, vol. 2, no. 2, pp. 363-368.
37. Lundberg S., Qureshi A.R., Olivecrona S., Gunnarsson I. et al. FGF23, albuminuria, and disease progression in patients with chronic IgA nephropathy. Clin J Am Soc Nephrol, 2012, vol. 7, no. 5, pp. 727-734.
38. De Seigneux S., Courbebaisse M., Rutkowski J.M., Wilhelm-Bals A., Metzger M., Khodo S.N., Nephro Test Study Group. Proteinuria increases plasma phosphate by altering its tubular handling. J Am Soc Nephrol, 2015, vol. 26, no. 7, pp. 1608-1618.
39. Feinstein S., Becker-Cohen R., Rinat C., Frishberg Y. Hyperphosphatemia is prevalent among children with nephrotic syndrome and normal renal function. Pediatr Nephrol, 2006, vol. 21, no. 10, pp. 1406-1412.
40. Frishberg Y., Feinstein S., Rinat C., Becker-Cohen R. al. The heart of children with steroid-resistant nephrotic syndrome: is it all podocin? J Am Soc Nephrol, 2006, vol. 17, pp. 227-231.
41. Meguro T., Hong C., Asai K., Takagi G., al. Cyclosporine Attenuates Pressure-Overload Hypertrophy in Mice While Enhancing Susceptibility to Decompensation and Heart Failure. Circ Res, 1999, vol. 84, pp. 735-740.
42. Strozecki P., Adamowicz A., Wlodarczyk Z., Manitius J. The influence of calcineurin inhibitors on pulse wave velocity in renal transplant recipients. Renal Fuilure, 2007, vol. 29.